Development and application of an ultrasensitive hybridization-based ELISA method for the determination of peptide-conjugated phosphorodiamidate morpholino …

U Burki, J Keane, A Blain, L O'Donovan… - Nucleic acid …, 2015 - liebertpub.com
U Burki, J Keane, A Blain, L O'Donovan, MJ Gait, SH Laval, V Straub
Nucleic acid therapeutics, 2015liebertpub.com
Antisense oligonucleotide (AON)-induced exon skipping is one of the most promising
strategies for treating Duchenne muscular dystrophy (DMD) and other rare monogenic
conditions. Phosphorodiamidate morpholino oligonucleotides (PMOs) and 2′-O-methyl
phosphorothioate (2′ OMe) are two of the most advanced AONs in development. The next
generation of peptide-conjugated PMO (P-PMO) is also showing great promise, but to
advance these therapies it is essential to determine the pharmacokinetic and biodistribution …
Antisense oligonucleotide (AON)-induced exon skipping is one of the most promising strategies for treating Duchenne muscular dystrophy (DMD) and other rare monogenic conditions. Phosphorodiamidate morpholino oligonucleotides (PMOs) and 2′-O-methyl phosphorothioate (2′OMe) are two of the most advanced AONs in development. The next generation of peptide-conjugated PMO (P-PMO) is also showing great promise, but to advance these therapies it is essential to determine the pharmacokinetic and biodistribution (PK/BD) profile using a suitable method to detect AON levels in blood and tissue samples. An enzyme-linked immunosorbent assay (ELISA)-based method, which shows greater sensitivity than the liquid chromatography–mass spectrometry method, is the method of choice for 2′OMe detection in preclinical and clinical studies. However, no such assay has been developed for PMO/P-PMO detection, and we have, therefore, developed an ultrasensitive hybridization-based ELISA for this purpose. The assay has a linear detection range of 5–250 pM (R2>0.99) in mouse serum and tissue lysates. The sensitivity was sufficient for determining the 24-h PK/BD profile of PMO and P-PMO injected at standard doses (12.5 mg/kg) in mdx mice, the dystrophin-deficient mouse model for DMD. The assay demonstrated an accuracy approaching 100% with precision values under 12%. This provides a powerful cost-effective assay for the purpose of accelerating the development of these emerging therapeutic agents.
Mary Ann Liebert